



Clinical trial results:

Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion

Summary

EudraCT number	2020-000095-38
Trial protocol	Outside EU/EEA
Global end of trial date	12 November 2019

Results information

Result version number	v1
This version publication date	22 May 2020
First version publication date	22 May 2020

Trial information

Trial identification

Sponsor protocol code	AVXS-101-CL-303
-----------------------	-----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03306277
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AveXis, Inc
Sponsor organisation address	2275 Half Day Road, Bannockburn, United States, IL 60015
Public contact	EMA Medical Information, AveXis Eu Ltd , +353 (1) 566-2364, medinfo.emea@avexis.com
Scientific contact	EMA Medical Information, AveXis Eu Ltd , +353 (1) 566-2364, medinfo.emea@avexis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002168-PIP01-17
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 November 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 November 2019
Global end of trial reached?	Yes
Global end of trial date	12 November 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

- Determine efficacy by demonstrating achievement of developmental milestone of functional independent sitting for at least 30 seconds at the 18 months of age visit.
- Determine the efficacy based on survival at 14 months of age. Survival is defined by avoidance of combined endpoint of either (a) death or (b) permanent ventilation.

Protection of trial subjects:

The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/GCP, applicable regulatory requirements and the AveXis' policy on Bioethics.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 October 2017
Long term follow-up planned	Yes
Long term follow-up rationale	Regulatory reason
Long term follow-up duration	15 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 22
Worldwide total number of subjects	22
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	1
Infants and toddlers (28 days-23 months)	21
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

22 participants were recruited at 12 study centres in the United States.

Pre-assignment

Screening details:

A screening period of up to 30 days occurred before treatment.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	AVXS-101
------------------	----------

Arm description:

Single dose of AVXS-101 administered as an intravenous (IV) infusion.

Arm type	Experimental
Investigational medicinal product name	AVXS-101
Investigational medicinal product code	
Other name	Onasemnogene Apeparvovec-xioi
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Participants received a single dose of AVXS-101 as an intravenous (IV) infusion.

Number of subjects in period 1	AVXS-101
Started	22
Completed	19
Not completed	3
Consent withdrawn by subject	1
Adverse event, non-fatal	1
Death	1

Baseline characteristics

Reporting groups

Reporting group title	Overall Study
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall Study	Total	
Number of subjects	22	22	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	1	1	
Infants and toddlers (28 days-23 months)	21	21	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	3.7		
standard deviation	± 1.6	-	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	10	10	
Race			
Units: Subjects			
White	11	11	
Black or African American	3	3	
Asian	2	2	
Other	6	6	
Ethnicity			
Units: Subjects			
Not Hispanic or Latino	18	18	
Hispanic or Latino	4	4	
Patient reported hospitalizations			
Units: Subjects			
Yes	17	17	
No	5	5	
Weight at baseline			
Units: kg			
arithmetic mean	5.8		
standard deviation	± 1.1	-	
Height/length at baseline			
Units: cm			

arithmetic mean	61.3		
standard deviation	± 4.3	-	

End points

End points reporting groups

Reporting group title	AVXS-101
Reporting group description:	Single dose of AVXS-101 administered as an intravenous (IV) infusion.

Primary: Achievement of independent sitting for at least 30 seconds

End point title	Achievement of independent sitting for at least 30 seconds ^[1]
-----------------	---

End point description:

This endpoint is a co-primary endpoint.

Independent sitting is defined as sitting for at least 30 seconds at the 18 months of age visit.

A one-sided Exact Binomial Test was used to test the null hypothesis of $p=0.1\%$ at significance level of 0.025. The corresponding 97.5% confidence intervals was estimated by the exact method for binomial proportions. It was assumed that the true response rate for the primary endpoint was actually zero (or as low as 0.1%) in the population of historical control; the first co-primary efficacy endpoint hypothesis was that the AVXS-101 treated participants achieve a response rate greater than 0.1%.

The two co-primary efficacy endpoints were assessed in sequence: The endpoint of functional independent sitting was assessed first and, only when this assessment met statistical significance was the endpoint of survival assessed.

End point type	Primary
----------------	---------

End point timeframe:

At 18 months of age visit

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This comparison is made to an assumed rate of zero 0. By definition, children with SMA Type 1 are never able to sit independently. Attachments have been added to depict the results.

End point values	AVXS-101			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: Participants	13			

Attachments (see zip file)	Achievement of Independent Sitting /Achievement of
-----------------------------------	--

Statistical analyses

No statistical analyses for this end point

Primary: Event-free survival

End point title	Event-free survival ^[2]
-----------------	------------------------------------

End point description:

The endpoint is a co-primary endpoint.

Survival is defined by the avoidance of combined endpoint of either death or permanent ventilation, which is defined by tracheostomy or by the requirement of ≥ 16 hours of respiratory assistance per day for ≥ 14 consecutive days in the absence of an acute reversible illness, excluding perioperative ventilation. Permanent ventilation is considered a surrogate for death. An acute reversible illness is defined as any condition other than SMA that results in increased medical intervention.

A two sample 2-sided Fischer's exact test was used to test the null hypothesis of $p=\text{historical}$ at the

significance level of 0.05. Participant-level data was drawn from the PNCr study with 25% participants surviving at 13.6 months.

The two co-primary efficacy endpoints were assessed in sequence: The endpoint of functional independent sitting was assessed first and, only when this assessment met statistical significance was the survival endpoint assessed.

End point type	Primary
----------------	---------

End point timeframe:

14 months of age

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was conducted against a population from a natural history study in children with SMA Type 1 conducted by the Pediatric Neuromuscular Clinical Research Network (Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy Type I and implications for clinical trials. *Neurol.* 2014;83(9):810-817.) Due to system limitations, the comparator population can not be displayed in this format. However, attachments have been added to depict these results.

End point values	AVXS-101			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: Participants	20			

Attachments (see zip file)	Event-free Survival /Primary Event Free Survival SA.pdf
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Secondary: Ability to thrive

End point title	Ability to thrive
-----------------	-------------------

End point description:

This is a co-secondary endpoint.

Ability to thrive is defined as achieving all of the following at 18 months of age:

- does not receive nutrition through mechanical support or other non-oral method
- ability to tolerate thin liquids as demonstrated through a formal swallowing test
- maintains weight

The two co-secondary endpoints were assessed in sequence: The endpoint of ability to thrive was assessed first and, only when this assessment met statistical significance was the endpoint of ventilatory support independence assessed. Comparison to the historical was made using 0.1% as comparison, as the percentage of participants who maintained ability to thrive was essentially 0.

One-sided exact binomial tests were executed for secondary efficacy analyses on the Intent to Treat (ITT) population.

The group used for comparison can be found at the following reference: Sproule RS, et al. *J Child Neurol.* 2012;27:845-851.

End point type	Secondary
----------------	-----------

End point timeframe:

At 18 months of age

End point values	AVXS-101			
Subject group type	Reporting group			
Number of subjects analysed	22 ^[3]			
Units: Participants	9			

Notes:

[3] - Two participants discontinued the study prior to 18 months.

Attachments (see zip file)	Ability to Thrive/Ability to thrive_Redacted.pdf
-----------------------------------	--

Statistical analyses

No statistical analyses for this end point

Secondary: Ventilatory support independence

End point title	Ventilatory support independence
-----------------	----------------------------------

End point description:

This is a co-secondary endpoint.

Ventilatory support independence is defined as requiring no daily ventilator support/usage at 18 months of age, excluding acute reversible illness and perioperative ventilation, through assessment of actual usage data captured from the device (Phillips Trilogy).

The two co-secondary endpoints were assessed in sequence: The endpoint of ability to thrive was assessed first and, only when this assessment met statistical significance was the endpoint of ventilatory support independence assessed. Comparison to the historical was made using 0.1% as comparison, as the percentage of participants who maintained independence from ventilatory support was essentially 0.

One-sided exact binomial tests were executed for secondary efficacy analyses on the Intent to Treat (ITT) population.

Two participants had Trilogy data at or after 18 months of age.

End point type	Secondary
----------------	-----------

End point timeframe:

At 18 months

End point values	AVXS-101			
Subject group type	Reporting group			
Number of subjects analysed	22 ^[4]			
Units: Participants	18			

Notes:

[4] - Two participants discontinued the study prior to 18 months.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 18 months of age

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	AVXS-101
-----------------------	----------

Reporting group description:

Single dose of AVXS-101 administered as an intravenous (IV) infusion.

Serious adverse events	AVXS-101		
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 22 (45.45%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	1		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Human metapneumovirus test positive			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transaminases increased			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Cardiac disorders Cyanosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 22 (4.55%) 0 / 1 0 / 0		
Nervous system disorders Hydrocephalus subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 22 (4.55%) 1 / 1 0 / 0		
Gastrointestinal disorders Dysphagia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 22 (4.55%) 0 / 1 0 / 0		
Respiratory, thoracic and mediastinal disorders Respiratory distress subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	4 / 22 (18.18%) 0 / 7 0 / 0		
Respiratory failure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 22 (9.09%) 0 / 2 0 / 0		
Acute respiratory failure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 22 (4.55%) 0 / 1 0 / 0		
Atelectasis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 22 (4.55%) 0 / 2 0 / 0		
Pneumonia aspiration			

subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory arrest			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bacterial tracheitis			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Device related infection			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia bacterial			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rhinovirus infection			

subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Product issues			
Device malfunction			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Abnormal weight gain			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Feeding disorder			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	AVXS-101		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	22 / 22 (100.00%)		
Vascular disorders			
Diastolic hypertension			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	12 / 22 (54.55%)		
occurrences (all)	26		
Reproductive system and breast disorders			
Use of accessory respiratory muscles			
subjects affected / exposed	5 / 22 (22.73%)		
occurrences (all)	7		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	7 / 22 (31.82%)		
occurrences (all)	10		
Respiratory distress			
subjects affected / exposed	3 / 22 (13.64%)		
occurrences (all)	3		
Respiration abnormal			
subjects affected / exposed	5 / 22 (22.73%)		
occurrences (all)	6		
Nasal congestion			
subjects affected / exposed	3 / 22 (13.64%)		
occurrences (all)	3		
Sleep apnoea syndrome			
subjects affected / exposed	3 / 22 (13.64%)		
occurrences (all)	3		
Tachypnoea			
subjects affected / exposed	3 / 22 (13.64%)		
occurrences (all)	3		
Respiratory track congestion			

subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Rhinorrhea subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Upper respiratory tract congestion subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Investigations			
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	6 / 22 (27.27%) 9		
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	5 / 22 (22.73%) 8		
Blood creatine phosphokinase MB increased subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Lymphocyte count decreased subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Weight decreased subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	4 / 22 (18.18%) 4		
Arthropod bite subjects affected / exposed occurrences (all)	3 / 22 (13.64%) 7		

<p>Congenital, familial and genetic disorders</p> <p>Pectus excavatum subjects affected / exposed occurrences (all)</p> <p>Asphyxiating thoracic dystrophy subjects affected / exposed occurrences (all)</p> <p>Cryptorchism subjects affected / exposed occurrences (all)</p> <p>High arched palate subjects affected / exposed occurrences (all)</p>	<p>3 / 22 (13.64%) 3</p> <p>2 / 22 (9.09%) 2</p> <p>2 / 22 (9.09%) 2</p> <p>2 / 22 (9.09%) 2</p>		
<p>Cardiac disorders</p> <p>Pericardial effusion subjects affected / exposed occurrences (all)</p>	<p>2 / 22 (9.09%) 2</p>		
<p>Nervous system disorders</p> <p>Muscle contractions involuntary subjects affected / exposed occurrences (all)</p>	<p>2 / 22 (9.09%) 3</p>		
<p>Blood and lymphatic system disorders</p> <p>Thrombocytopenia subjects affected / exposed occurrences (all)</p>	<p>2 / 22 (9.09%) 2</p>		
<p>Gastrointestinal disorders</p> <p>Constipation subjects affected / exposed occurrences (all)</p> <p>Teething subjects affected / exposed occurrences (all)</p> <p>Diarrhoea subjects affected / exposed occurrences (all)</p> <p>Gastroesophageal reflux disease</p>	<p>9 / 22 (40.91%) 11</p> <p>5 / 22 (22.73%) 6</p> <p>4 / 22 (18.18%) 4</p>		

subjects affected / exposed occurrences (all)	4 / 22 (18.18%) 4		
Vomiting subjects affected / exposed occurrences (all)	4 / 22 (18.18%) 8		
Abdominal distension subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Dysphagia subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Haematochezia subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	5 / 22 (22.73%) 5		
Dermatitis atopic subjects affected / exposed occurrences (all)	3 / 22 (13.64%) 3		
Eczema subjects affected / exposed occurrences (all)	3 / 22 (13.64%) 3		
Dermatitis contact subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 3		
Dermatitis diaper subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 4		
Urticaria subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		
Musculoskeletal and connective tissue disorders			

Scoliosis			
subjects affected / exposed	9 / 22 (40.91%)		
occurrences (all)	12		
Deformity thorax			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Joint contracture			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Kyphosis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Torticollis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	11 / 22 (50.00%)		
occurrences (all)	28		
Conjunctivitis			
subjects affected / exposed	3 / 22 (13.64%)		
occurrences (all)	3		
Otitis media			
subjects affected / exposed	3 / 22 (13.64%)		
occurrences (all)	4		
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	3		
Gastroenteritis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Nasopharyngitis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Metabolism and nutrition disorders			

Feeding disorder subjects affected / exposed occurrences (all)	3 / 22 (13.64%) 4		
Weight gain poor subjects affected / exposed occurrences (all)	2 / 22 (9.09%) 2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 October 2017	Updated to include cardiac enzyme monitoring (CK-MB), added AVXS-101 dose determined through ddPCR with AveXis GMP product, and to require a total of 15 participants meeting the ITT criteria to be enrolled.
21 December 2017	Updated to clarify the data points which require review for the first three participants prior to continuing with enrollment. Additionally, a Day -1 CHOP-INTEND assessment was added.
04 October 2018	Updated to included updated and recent GLP toxicology data, to provide additional cardiac monitoring for patient safety, standardize infusion times within protocol, allow laboratory samples to be processed locally in certain instances, and to exclude participants from Bayley scales where English is not their first language to preserve the validity of the Bayley scales.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/22467740>